Company description

CSTL, also known as Castle Biosciences Inc., is a leading diagnostic and treatment company focused on improving cancer patient outcomes. They utilize innovative proprietary technology, such as gene expression profiling, to provide personalized treatment options for patients. This technology, combined with their team of experts, allows CSTL to accurately assess the risk of cancer recurrence and help physicians make informed treatment decisions. The company's primary product, DecisionDx®-Melanoma, is a groundbreaking test that helps identify the risk of metastasis in patients with melanoma. In addition, CSTL offers tests for uveal melanoma, cutaneous squamous cell carcinoma, and other cancers. Since its launch in 2008, CSTL has rapidly expanded its reach and now offers its products and services to healthcare providers across the United States and globally. Their commitment to accelerating cancer care and delivering accurate, personalized diagnostic tools has solidified their reputation as a trusted and reliable company in the medical community.